Receptor News and Research

RSS

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

6 Nov 2015

New tool could help identify patients most likely to benefit from chemoprevention

A team of scientists, led by researchers at University of California, San Diego Moores Cancer Center and The University of Texas MD Anderson Cancer Center, report that a genetic biomarker called loss of heterozygosity or LOH is able to predict which patients with premalignant mouth lesions are at highest risk of developing oral cancer.

6 Nov 2015

Circulating protein predicts risk of chronic kidney disease

Make room, cholesterol. A new disease marker is entering the medical lexicon: suPAR, or soluble urokinase-type plasminogen activator receptor.

6 Nov 2015

Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012) in the United States.

6 Nov 2015

MD Anderson Cancer Center, CytomX to study probody-enabled CAR-NK cell therapies

CytomX Therapeutics, a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today entered into a collaboration with The University of Texas MD Anderson Cancer Center to research Probody-enabled chimeric antigen receptor natural killer (CAR-NK) cell therapies, to be known as ProCAR-NK cell therapies.

6 Nov 2015

Researchers identify new regulatory pathway that may play vital role in basal-like breast cancer

Researchers have identified a new regulatory pathway that may play an important role in basal-like breast cancer (BLBC), a particularly aggressive form of breast cancer often referred to as "triple negative." This pathway may serve as a target for the development of an effective therapeutic.

5 Nov 2015

Estrogen-like drug may not be beneficial to women with Alzheimer's dementia

An estrogen-like drug, raloxifene, has no demonstrated benefit on memory and thinking skills for women with dementia due to Alzheimer's disease, according to a study published in the November 4, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

5 Nov 2015

CK5 protein marks ovarian cancer likely to be resistant to cisplatin

A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin.

5 Nov 2015

International research project examines effectiveness of tried and tested medicines for different diseases

The Medical University of Vienna is coordinating an international research project, which investigates the effectiveness of tried and tested medicines for the treatment of some of the heaviest burdens of our modern society including diseases such as cancer, diabetes and cardiovascular diseases. One molecule that these disorders have in common is a receptor known as the calcium-sensing receptor (CaSR), which is the molecular starting point of this project.

4 Nov 2015

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015

$Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture$

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced the initiation of dosing in the company's Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture.

3 Nov 2015

Discovery offers promising alternative to current therapies for AMD and ROP

A research team led by scientists at Beth Israel Deaconess Medical Center and the University of New Mexico School of Medicine has identified a small molecule that treats animal models of aged macular degeneration (AMD) and retinopathy of prematurity (ROP) by preventing the overgrowth of blood vessels that are characteristic of these two retinal diseases.

3 Nov 2015

Rotation model provides explanation of ligand activation mechanism of dimeric receptors

"This 'rotation model', which made the cover of BioEssays, represents a true paradigm shift in the membrane receptor field," stated Prof. Pierre De Meyts, a renowned researcher of insulin and receptor binding for almost half a century and one of the reviewers of the paper by Prof. Ichiro Maruyama, the head of the Information Processing Biology Unit at Okinawa Institute of Science and Technology Graduate University.

31 Oct 2015

Gut bacteria may increase risk of metabolic syndrome

An excess of bacteria in the gut can change the way the liver processes fat and could lead to the development of metabolic syndrome, according to health researchers.

30 Oct 2015

Scientists one step closer to developing new treatment for inflammatory bowel disease

For patients with inflammatory bowel disease, the possibility of taking a single pill to bring long-lasting relief might seem too good to be true. Scientists at the Lewis Katz School of Medicine at Temple University are on the brink of making that happen, thanks to a recent proof-of-concept study, in which the severity of a form of inflammatory bowel disease in mice was dramatically reduced with one oral dose of a protein isolated from a bacterial biofilm.

30 Oct 2015

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Transition Therapeutics Inc. announced today that Transition Therapeutics Ireland Limited has entered into an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women's Hospital.

30 Oct 2015

Adelaide researchers identify key protein involved in 'super-inflammatory' immune response

Researchers have made another important step in the progress towards being able to block the development of multiple sclerosis (MS) and other autoimmune diseases.

29 Oct 2015

New TSRI study highlights urgent need for new treatments to fight growing cancer metastases

A new study from scientists at The Scripps Research Institute helps explain why cancer metastasis is so hard to stop.

29 Oct 2015

Breastfeeding associated with lower risk of developing hormone-receptor negative breast cancer

A large international study shows that breastfeeding is associated with a lower risk of developing an aggressive form of breast cancer called hormone-receptor negative. This new combined evidence shows the risk was reduced by up to 20% in women who breastfed.

29 Oct 2015

Pre-clinical study demonstrates positive effects of advanced prebiotic on neuro-inflammation, anxiety

Clasado Biosciences Limited, the producers and suppliers of the second generation prebiotic Bimuno(R) (B-GOS), a unique trans-galactooligosaccharide, and the Department of Psychiatry, University of Oxford, today announce the results of their latest pre-clinical study demonstrating a major role of the unique carbohydrate complex Bimuno against neuro-inflammation and anxiety.

28 Oct 2015

Receptor News and Research

Viralytics enters into clinical trial collaboration agreement with MSD

New tool could help identify patients most likely to benefit from chemoprevention

Circulating protein predicts risk of chronic kidney disease

Hutchison MediPharma begins sulfatinib Phase I trial in US

MD Anderson Cancer Center, CytomX to study probody-enabled CAR-NK cell therapies

Researchers identify new regulatory pathway that may play vital role in basal-like breast cancer

Estrogen-like drug may not be beneficial to women with Alzheimer's dementia

CK5 protein marks ovarian cancer likely to be resistant to cisplatin

International research project examines effectiveness of tried and tested medicines for different diseases

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Viking begins VK5211 Phase 2 trial in patients recovering from hip fracture

Discovery offers promising alternative to current therapies for AMD and ROP

Rotation model provides explanation of ligand activation mechanism of dimeric receptors

Gut bacteria may increase risk of metabolic syndrome

Scientists one step closer to developing new treatment for inflammatory bowel disease

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Adelaide researchers identify key protein involved in 'super-inflammatory' immune response

New TSRI study highlights urgent need for new treatments to fight growing cancer metastases

Breastfeeding associated with lower risk of developing hormone-receptor negative breast cancer

Pre-clinical study demonstrates positive effects of advanced prebiotic on neuro-inflammation, anxiety

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News